PharmaPoint: Non-Small Cell Lung Cancer - France Drug Forecast and Market Analysis to 2022


#174346

189pages

GlobalData

$ 4995

In Stock


Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

Growth in the French NSCLC market is expected to contract, the decline will be driven by the loss of patent protection for the key marketed therapies Alimta, Avastin, Iressa and Tarceva combined with reimbursement pressures limiting the ability of new companies to gain reimbursement approval for their pipeline agents.

Scope

  • Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting France NSCLC market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in France.
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 13

3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology and Histology 14
3.1.3 NSCLC Biomarkers 15
3.1.4 Quality of Life 16
3.2 Symptoms 17

4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Diagnosis 20
4.1.2 Clinical Staging 21
4.1.3 Screening and Early Detection 23
4.1.4 Localized Procedures and Therapies 24
4.1.5 Systemic Chemotherapy 25
4.1.6 Targeted Therapy 26
4.2 France 29
4.2.1 Diagnosis 29
4.2.2 Clinical Practice 29

5 Competitive Assessment 32
5.1 Overview 32
5.2 Strategic Competitor Assessment 33
5.3 Product Profiles Major Brands, Chemotherapies 35
5.3.1 Alimta (pemetrexed disodium) 35
5.4 Product Profiles Major Brands, Targeted Therapies 39
5.4.1 Iressa (gefitinib) 39
5.4.2 Tarceva (erlotinib hydrochloride) 44
5.4.3 Xalkori (crizotinib) 50
5.4.4 Avastin (bevacizumab) 54

6 Opportunity and Unmet Need 58
6.1 Overview 58
6.2 Improved Overall Survival and Less Toxicity 59
6.3 Treatments for Patients with Acquired TKI Resistance 60
6.4 Better Treatment Options for Squamous Patients 60
6.5 Preventing Relapse or Recurrence 61
6.6 More Efficacious Second-Line Therapies 61
6.7 Increased Availability of Mutation Testing 62
6.8 More Cost-Effective Therapies 63
6.9 Unmet Needs Gap Analysis 63

7 Pipeline Assessment 67
7.1 Overview 67
7.2 Promising Drugs in Clinical Development 67
7.2.1 onartuzumab (MetMab) 71
7.2.2 necitumumab (IMC-11F8) 77
7.2.3 ramucirumab (IMC-1121B) 82
7.2.4 custirsen (OGX-011) 86
7.2.5 ganetespib (STA-9090) 91
7.2.6 nintedanib (BIBF1120) 97
7.2.7 Gilotrif (afatinib) 101
7.2.8 dacomitinib (PF-00299804) 107
7.2.9 LDK378 112
7.2.10 Yervoy (ipilimumab) 117
7.2.11 nivolumab (BMS936558) 121
7.2.12 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 127
7.2.13 Halaven (eribulin mesylate) 131

8 Market Outlook 136
8.1 France 136
8.1.1 Forecast 136
8.1.2 Key Events 139
8.1.3 Drivers and Barriers 140

9 Appendix 142
9.1 Bibliography 142
9.2 Abbreviations 161
9.3 Methodology 165
9.4 Forecasting Methodology 165
9.4.1 Number of NSCLC Patients Currently Seeking Treatment 165
9.4.2 Percent Drug-treated Patients 166
9.4.3 Drugs Included in Each Therapeutic Class 166
9.4.4 Launch and Patent Expiry Dates 167
9.4.5 General Pricing Assumptions 168
9.4.6 Individual Drug Assumptions 171
9.4.7 Generic Erosion 179
9.4.8 Pricing of Pipeline Agents 180
9.5 Physicians and Specialists Included in This Study 182
9.6 Survey of Prescribing Physicians 184
9.7 About the Authors 185
9.7.1 Authors 185
9.7.2 Epidemiologists 186
9.7.3 Global Head of Healthcare 187
9.8 About GlobalData 188
9.9 Disclaimer 188

Table 1: Symptoms of Disease NSCLC 18
Table 2: Treatment Guidelines for NSCLC 20
Table 3: Stage Definitions for NSCLC 22
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 28
Table 5: Leading Treatments for NSCLC 35
Table 6: Product Profile Alimta (pemetrexed disodium) 37
Table 7: Alimta SWOT Analysis, 2013 39
Table 8: Product Profile Iressa (gefitinib) 41
Table 9: Iressa SWOT Analysis, 2013 44
Table 10: Product Profile Tarceva (erlotinib hydrochloride) 46
Table 11: Tarceva SWOT Analysis, 2013 49
Table 12: Product Profile Xalkori (crizotinib) 51
Table 13: Xalkori SWOT Analysis, 2013 54
Table 14: Product Profile Avastin (bevacizumab) 55
Table 15: Avastin SWOT Analysis, 2013 57
Table 16: Overall Unmet Needs Current Level of Attainment 59
Table 17: Clinical Unmet Needs Gap Analysis, 2013 64
Table 18: Non-Small Cell Lung Cancer Phase I-II Pipeline, 2013 68
Table 19: NSCLC Phase III Pipeline, 2013 69
Table 20: NSCLC Advantages and Disadvantages of Therapeutic Classes 70
Table 21: Product Profile onartuzumab (MetMab) 72
Table 22: onartuzumab SWOT Analysis, 2013 77
Table 23: Product Profile necitumumab (IMC-11F8) 78
Table 24: necitumumab SWOT Analysis, 2013 81
Table 25: Product Profile ramucirumab (IMC-1121B) 82
Table 26: ramucirumab SWOT Analysis, 2013 86
Table 27: Product Profile custirsen (OGX-011) 87
Table 28: custirsen SWOT Analysis, 2013 91
Table 29: Product Profile ganetespib (STA-9090) 92
Table 30: ganetespib SWOT Analysis, 2013 97
Table 31: Product Profile nintedanib (BIBF-1120) 98
Table 32: nintedanib SWOT Analysis, 2013 101
Table 33: Product Profile Gilotrif (afatinib) 102
Table 34: Gilotrif SWOT Analysis, 2013 107
Table 35: Product Profile dacomitinib (PF-00299804) 108
Table 36: dacomitinib SWOT Analysis, 2013 111
Table 37: Product Profile LDK378 113
Table 38: LDK378 SWOT Analysis, 2013 117
Table 39: Product Profile Yervoy (ipilimumab) 118
Table 40: Yervoy SWOT Analysis, 2013 121
Table 41: Product Profile nivolumab (BMS936558) 122
Table 42: nivolumab SWOT Analysis, 2013 127
Table 43: Product Profile GSK1572932A (MAGE-A3 immunotherapy) 128
Table 44: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 131
Table 45: Product Profile Halaven (eribulin mesylate) 132
Table 46: Halaven SWOT Analysis, 2013 135
Table 47: Sales Forecasts ($m) for NSCLC in France, 2012-2022 137
Table 48: Key Events Impacting Sales for NSCLC in France, 2012-2022 139
Table 49: NSCLC Market in France Drivers and Barriers, 20122022 140
Table 50: Five Year Prevalence 166
Table 51: Key Launch Dates 167
Table 52: Key Patent Expiries 168
Table 53: Physicians Surveyed by Country 184
Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 20122022 70
Figure 2: Sales for NSCLC in France by Drug, 20122022 138